Tipiracil/trifluridine

Drug Profile

Tipiracil/trifluridine

Alternative Names: Lonsurf; S 95005/TAS-102; T15, T20; T15/T20; TAS-102; Trifluridine/tipiracil; Trifluridine/tipiracil hydrochloride

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Developer 3SBio; Boehringer Ingelheim; National Cancer Center (Tokyo); Servier; Taiho Pharmaceutical
  • Class Antineoplastics; Nucleosides; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase III Gastric cancer
  • Phase II Oesophageal cancer; Small cell lung cancer
  • Phase I Gastrointestinal cancer; Solid tumours

Most Recent Events

  • 13 Feb 2017 The Scottish Medicines Consortium accepts tipiracil/trifluridine for the treatment of Colorectal cancer
  • 21 Dec 2016 Chemical structure information added
  • 25 Nov 2016 Taiho Pharmaceutical initiates enrolment in a phase I trial for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Japan (UMIN000019828)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top